Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series

Simone Guerrieri; Martina Rubin; Irene Gattuso; Chiara Zanetta; Angela Genchi; Paolo Preziosa; Maria A. Rocca; Massimo Filippi; Lucia Moiola

doi:10.1007/s00415-024-12342-z

Related publications

Article2008

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?

T. Korteweg, Marco Rovaris, Veronica Neacsu, Massimo Filippi, Giancarlo Comi, Bernard M.J. Uitdehaag, DL Knol, CH Polman, Frederik Barkhof, Hugo Vrenken

Article2018

Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

Emma L. Mitchell, Peter K. H. Lau, Chloe Khoo, David Liew, Jessica Leung, Bonnia Liu, Adam Rischin, Albert G. Frauman, Damien Kee, Kortnye Smith, Benjamin Brady, Danny Rischin, Andrew Gibson, Linda Mileshkin, Oliver Klein, Andrew Weickhardt, Surein Arulananda, Mark Shackleton, Grant A. McArthur, Andrew J.K. Östör, Jonathan Cebon, Benjamin Solomon, Russell Buchanan, Ian P. Wicks, Serigne Lo, Rodney J. Hicks, Shahneen Sandhu

Article2019

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

Chiara Zanetta, Micaela Robotti, Agostino Nozzolillo, Francesca Sangalli, Giuseppe Liberatore, Eduardo Nobile‐Orazio, Massimo Filippi, Lucia Moiola

Preprint2023

Supplementary 1 from How Many Deaths from Colorectal Cancer Can Be Prevented by 2030? A Scenario-Based Quantification of Risk Factor Modification, Screening, and Treatment in Norway

Katrine Damgaard Skyrud, Tor Åge Myklebust, Freddie Ian Bray, Morten Eriksen, Thomas de Lange, Inger Kristin Larsen, Bjørn Møller

Preprint2023

Supplementary 1 from How Many Deaths from Colorectal Cancer Can Be Prevented by 2030? A Scenario-Based Quantification of Risk Factor Modification, Screening, and Treatment in Norway

Katrine Damgaard Skyrud, Tor Åge Myklebust, Freddie Ian Bray, Morten Eriksen, Thomas de Lange, Inger Kristin Larsen, Bjørn Møller

Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series

Discussion(0)

Related publications

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?

Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

Supplementary 1 from How Many Deaths from Colorectal Cancer Can Be Prevented by 2030? A Scenario-Based Quantification of Risk Factor Modification, Screening, and Treatment in Norway

Supplementary 1 from How Many Deaths from Colorectal Cancer Can Be Prevented by 2030? A Scenario-Based Quantification of Risk Factor Modification, Screening, and Treatment in Norway